What ChondroFiller does — and why it differs from a standard injection

Faced with a diagnosis of a focal cartilage defect, many patients ask the same question: is ChondroFiller just another injection, or does it actually do something to the joint? The answer matters, because it determines whether the treatment is managing symptoms or addressing the underlying structural problem.

ChondroFiller® liquid is a CE-marked Class III medical device — the highest regulatory tier for medical devices in Europe. It is not a painkiller, not a lubricant, and not a permanent filler. It is an injectable collagen scaffold: a material that, once placed inside the joint, forms a three-dimensional fibrillar structure that gives the body's own repair cells a framework to work within.

At London Cartilage Clinic, it is delivered as an ultrasound-guided outpatient injection — a clinic appointment, not an operating theatre. The product contains no donor or laboratory-grown cells. Instead, it works through a process called acellular matrix-induced chondrogenesis: the scaffold recruits the patient's own progenitor cells from the surrounding tissue, directing them towards cartilage repair. Nothing is added to the joint except the collagen matrix itself.

This distinguishes ChondroFiller clearly from hyaluronic acid injections, which lubricate and cushion the joint but do not repair it, and from permanent hydrogels such as Arthrosamid, which act as a mechanical filler rather than a regenerative scaffold. ChondroFiller is indicated for focal articular cartilage defects up to 6 cm²; it is not a treatment for widespread osteoarthritis.

The sections that follow explain how the scaffold works once it is inside the joint, and what the clinical evidence shows about the quality and durability of the repair it supports.

The collagen scaffold: what goes in and why native Type I matters

The material itself is a solution of native Type I collagen, derived from murine tissue via acid extraction — a process that preserves the protein's natural triple-helical structure. That structural detail is not a manufacturing footnote: it is what separates this scaffold from gelatin.

Gelatin is denatured collagen — the same protein after heat or chemical processing has unravelled its triple helix. Research comparing native and denatured collagen scaffolds directly found that chondrocytes adhered, proliferated, and redifferentiated significantly better on native constructs; in vivo, native collagen also drove superior cartilage and subchondral bone regeneration. The triple helix is the biologically active shape — the form that repair cells recognise and respond to.

On injection, the liquid behaves quite differently from a standard intra-articular injection: it does not stay fluid. Contact with the joint environment triggers rapid in situ polymerisation, converting the solution into a fibrillar gel scaffold within the defect. This transition from liquid to structured matrix is what creates the three-dimensional framework for host cell recruitment described in the section above.

The collagen's murine origin carries a theoretical immunogenicity consideration. The clinical record is reassuring: the manufacturer's clinical evaluation reports a complaint rate of approximately 0.06%. As that figure derives from manufacturer-sponsored data rather than independent post-market surveillance, it represents a provisional benchmark — a useful signal, but one that independent long-term registries have not yet confirmed.

How the gel scaffold recruits the body's own repair cells

Once the scaffold has solidified within the defect, three overlapping biological processes begin — and none of them require injected cells or growth factors.

The fibrillar gel provides two things simultaneously: a physical surface that repair cells can adhere to and migrate along, and a chemical signal that draws mesenchymal progenitor cells — from the surrounding synovium and subchondral bone — towards the site of damage. This chemotactic quality distinguishes the scaffold from a passive mechanical filler; it actively recruits the body's own repair machinery.

Before those cells can commit to repairing cartilage, the local environment must first shift away from inflammation. Research into Type I collagen hydrogels has shown that the scaffold reprogrammes synovial macrophages from a pro-inflammatory state (M1) to a reparative one (M2) — switching the joint, in effect, from breakdown mode to repair mode. A 2024 study published in Acta Biomaterialia found that this immune-environment shift also suppressed cartilage fibrosis and hypertrophy, helping to preserve the joint's biological balance as repair proceeds.

With the immune environment rebalanced, the recruited progenitor cells encounter a three-dimensional scaffold that guides chondrogenic differentiation — steering them towards cartilage-forming behaviour. Studies in collagen scaffold models have demonstrated mesenchymal cells migrating from subchondral bone through the calcified cartilage layer and producing cartilage-type matrix without any exogenous instruction. The scaffold itself is temporary: it is gradually remodelled and replaced by the body's own repair tissue rather than persisting in the joint indefinitely.

From gel to repair tissue: how the scaffold matures over time

Most regenerative therapies produce their benefit gradually — and ChondroFiller is no exception. Understanding that timeline helps patients interpret their recovery rather than misjudge it.

MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) is an MRI-based scoring system that tracks how completely a defect fills and how well the new tissue integrates with the surrounding cartilage. In published European studies, ChondroFiller's MOCART scores begin at a mean of 65.3 at four weeks post-injection — indicating partial early filling — and rise to 81.6 at one year, stabilising across multiple cohorts in the range of 81.6 to 84.3. A score above 80 signifies more than 80% defect filling with good structural integration on imaging.

This progression reflects two processes unfolding in sequence. In the early weeks the gel scaffold provides a physical matrix that cushions the worn articular surface while recruited progenitor cells begin to populate the fibrillar framework. Over the following months those cells differentiate and lay down repair tissue, progressively replacing the original collagen scaffold with the patient's own matrix. The scaffold is a temporal framework — not a permanent filler — and the MRI trajectory is the biological record of that substitution happening.

For patients, the practical implication is a repair arc measured in months rather than days. Functional improvement tracks this biological timeline, and the imaging data confirm that meaningful tissue maturation continues well beyond the point of first clinical change.

Clinical outcomes at one and three years

Three years of functional data provide the most compelling anchor in the outcomes literature. The Jerosch et al. post-market clinical follow-up study recorded a mean IKDC improvement of 32.4 points — IKDC being a validated knee function score running from 0 to 100 — sustained and marginally increased at the three-year assessment, with patients reaching a mean score of 80. Across the broader European evidence base, that approximately 30-point gain is consistent, and it exceeds the Minimal Clinically Important Difference of 16.7 points by more than double.

The MOCART scores at one year — 81.6 to 84.3 across studies — confirm that functional recovery tracks genuine structural repair rather than symptom suppression alone. These figures sit alongside a reported complication rate of approximately zero and a reoperation rate in the region of 3–8% in published series.

Context matters here. The clinical evidence available to date is manufacturer-sponsored or drawn from the manufacturer's Clinical Evaluation Report (CER v09, April 2025); no independent randomised controlled trial has been published directly comparing injectable ChondroFiller against microfracture or ACI. Follow-up beyond three years has not been reported. The gains documented within those limits are large, consistent, and durable to the horizon of available data — but an independent evidence base would strengthen confidence further, and that absence is the appropriate caveat for both patients and referring clinicians weighing these findings.

When ChondroFiller is the right pathway — and what assessment involves

Candidacy begins with defect geometry. ChondroFiller suits focal articular cartilage lesions — those produced by injury, osteochondritis dissecans, or localised early wear — rather than the diffuse joint-space loss of established osteoarthritis. As the device specification indicates, the indication extends to defects of up to 6 cm², a range that microfracture cannot reliably cover; that technique's evidence base is broadly limited to lesions under 2–4 cm², and the fibrocartilage it produces offers inferior mechanical durability compared with the hyaline-like repair tissue the scaffold evidence records.

Surgical pathways — ACI, MACI — remain appropriate alternatives where defect characteristics or subchondral bone status make an injectable scaffold unsuitable. Their functional gains are broadly comparable, but the procedural profile is considerably more demanding, and published reoperation figures run substantially higher than those in the ChondroFiller evidence base reviewed in the preceding section. That comparison is not an argument against surgery where surgery is indicated; it is context for a decision that requires individual clinical assessment.

MRI is the standard pre-treatment evaluation tool: it characterises defect size, depth, and subchondral bone integrity — detail that symptom history alone cannot supply and that shapes the choice between injection and surgery.

Taken together, the mechanism and outcomes data trace a coherent picture: an acellular collagen scaffold placed under ultrasound guidance that progressively matures into durable structural repair tissue. Whether that durability holds beyond three years remains the outstanding clinical question. For patients in London seeking a specialist cartilage assessment, Professor Paul Y. F. Lee at London Cartilage Clinic, Harley Street, leads the evaluation pathway, and initial enquiries can be made at londoncartilage.com.

1. [1] Combination of a Collagen Scaffold and an Adhesive Hyaluronan-Based Hydrogel for Cartilage Regeneration: A Proof of Concept in an Ovine Model. (2021). https://doi.org/10.1177/1947603521989417 https://doi.org/10.1177/1947603521989417
2. [2] Shape-memory collagen scaffold for enhanced cartilage regeneration: native collagen versus denatured collagen. (2018). https://doi.org/10.1016/j.joca.2018.06.004 https://doi.org/10.1016/j.joca.2018.06.004
3. [3] Collagen-based hydrogels induce hyaline cartilage regeneration by immunomodulation and homeostasis maintenance. (2024). https://doi.org/10.1016/j.actbio.2024.07.018 https://doi.org/10.1016/j.actbio.2024.07.018